Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri scMRD Assay for AML. Learn More
X
Scientific presentation

Issues faced when using targeted NGS panels in the clinic for diagnosis, prognosis, and treatment


Alexander Perl, MD
Catherine Smith, MD

Description

Large cancer centers have adopted Next Generation Sequencing (NGS) in the clinic for diagnosis, prognosis, and treatment decisions. Dr. Catherine Smith, from UCSF, discusses the issues faced with targeted panels in the clinic and the differences between amplicon and hybridization methods. While Dr. Alexander Perl, from the University of Pennsylvania, discusses the findings in their collaborative CHRYSALIS study of the FLT3 inhibitor Gilteritinib in relapsed/refractory AML where they used quantifiable single-cell DNA analysis to enable dynamic therapy selection.



VIEW


Scientific presentation
AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility
Aaron Llanso
AMP 2022 (2022)
Scientific presentation
Molecular Analysis of Acute Myeloid Leukemia in Morphologic Remission
Sanam Loghavi, MD
AMP 2022 (2022)
Scientific presentation
Considerations, Strategies, and Advances in Early Drug Development to Mitigate Clinical Holds and Achieve Successful CGT Outcomes
Azadeh Golipour, PhD, AVROBIO
J. Kelly Ganjei, AmplifyBio
Scott R. Burger, MD, Advanced Cell and Gene Therapy
Matthew Cato
(2022)
Scientific presentation
Overview on Mission Bio’s Applications
Simone Formisano
Mission Bio EU Heme Symposium (2022)
REQUEST QUOTE